influenza
infecti
diseas
caus
influenza
virus
orthomyxovirida
famili
continu
evolut
viru
caus
season
epidem
time
time
pandem
human
popul
furthermor
due
appear
influenzalik
ill
diagnosi
diseas
basi
clinic
symptom
possibl
outbreak
note
case
respiratori
infect
variou
clinic
symptom
caus
viru
hand
set
symptom
caus
differ
virus
eg
parainfluenza
adenoviru
rhinoviru
coronaviru
reason
laboratori
confirm
influenza
viru
infect
crucial
influenza
surveil
essenti
evalu
effect
vaccin
antivir
drug
laboratori
diagnosi
influenza
includ
confirm
presenc
influenza
viru
antigen
materi
collect
patient
serolog
evid
infect
influenza
viru
detect
increas
specif
antibodi
patient
serum
brydak
major
line
defens
influenza
infect
antibodi
direct
two
glycoprotein
expos
surfac
virion
hemagglutinin
ha
neuraminidas
na
johansson
et
al
furthermor
evolut
influenza
viru
evid
case
surfac
protein
ha
na
antigen
constantli
chang
due
antigen
pressur
highli
immunogen
antibodi
produc
respons
viral
infect
specif
particular
subtyp
hemagglutinin
neuraminidas
give
complet
protect
influenza
viru
strain
nicholson
et
al
presenc
hemagglutinin
antibodi
antiha
provid
protect
infect
specif
strain
influenza
viru
also
might
allevi
symptom
diseas
case
infect
anoth
variant
viru
caus
occurr
socal
crossreact
antibodi
shown
subtypespecif
antiha
antibodi
decreas
infect
viru
subtyp
disrupt
prolifer
releas
viral
particl
infect
ekiert
et
al
epstein
price
thorsbi
et
al
reason
regular
vaccin
essenti
reduc
impact
season
influenza
influenza
prevent
season
vaccin
protect
infect
current
circul
virus
give
crossprotect
reduc
viral
replic
acceler
viral
clearanc
thu
reduc
sever
diseas
world
health
organ
lead
global
influenza
surveil
give
season
recommend
influenza
viru
strain
includ
vaccin
upcom
epidem
season
antiha
antibodi
titer
determin
correspond
reduct
risk
contract
influenza
popul
hobson
et
al
assum
high
titer
antiha
antibodi
provid
protect
influenza
infect
furthermor
valu
titer
vaccin
requir
european
agenc
evalu
medicin
product
assess
vaccin
committe
proprietari
medicin
product
hand
antina
antibodi
even
high
titer
support
resist
prevent
influenza
infect
howev
shown
antina
antibodi
block
replic
process
allevi
sever
infect
reduc
incid
diseas
brydak
serolog
method
detect
antiinfluenza
antibodi
includ
among
other
hemagglutin
inhibit
hai
test
neuraminidas
inhibit
ni
test
serolog
test
use
diagnost
purpos
also
evalu
resist
popul
result
natur
infect
vaccin
influenza
laboratori
use
hemagglutin
inhibit
test
serolog
diagnosi
method
base
abil
antiha
antibodi
inhibit
virusinduc
agglutin
erythrocyt
global
influenza
surveil
network
simpl
inexpens
rapid
test
small
amount
reagent
use
due
high
cost
laborconsumpt
mani
laboratori
determin
level
antibodi
neuraminidas
inhibit
test
brydak
record
number
case
influenza
influenzalik
ill
depend
report
health
care
worker
poland
done
local
sanitari
epidemiolog
station
thereaft
data
form
weekli
report
sent
nation
institut
public
health
nation
institut
hygien
voivodeship
sanitari
epidemiolog
station
two
type
influenza
vaccin
current
avail
poland
inactiv
split
virion
subunit
split
type
vaccin
contain
inactiv
split
viru
wherea
subunit
type
contain
viral
glycoprotein
hemagglutinin
neuraminidas
note
alreadi
mani
influenza
season
numer
local
govern
offer
free
influenza
vaccin
peopl
year
age
often
belong
highrisk
group
health
despit
proport
peopl
vaccin
diminish
season
season
epidem
season
popul
vaccin
influenza
brydak
epidem
season
mild
intens
comparison
previou
season
total
number
case
influenza
influenzalik
ill
regist
poland
season
incid
per
popul
caus
death
result
complic
influenza
gi
paper
describ
determin
level
antibodi
hemagglutinin
influenza
virus
present
sera
peopl
differ
age
group
epidem
season
serum
sampl
peopl
age
group
geometr
mean
titer
antiha
antibodi
sera
collect
peopl
differ
age
group
epidem
season
shown
fig
highest
level
antibodi
hemagglutinin
found
age
group
gmt
antibodi
slightli
lower
age
group
low
age
group
almost
level
antibodi
lowest
level
antibodi
observ
age
group
case
hemagglutinin
highest
geometr
mean
titer
year
old
group
age
group
valu
similar
level
type
b
hemagglutinin
observ
level
antibodi
highest
group
year
lower
group
year
lowest
group
year
gmt
respect
almost
ident
geometr
mean
titer
observ
age
group
conclus
highest
gmt
titer
observ
age
group
differ
type
antiha
antibodi
domin
group
b
respect
lowest
geometr
mean
titer
antibodi
direct
ha
observ
children
age
year
protect
rate
percentag
peopl
protect
titer
antiha
antibodi
least
vaccin
depend
age
achiev
differ
valu
peopl
age
year
peopl
year
age
brydak
howev
protect
rate
exceed
age
group
fig
highest
level
protect
rate
observ
hemagglutinin
strain
age
group
analysi
protect
rate
respect
age
group
includ
three
type
hemagglutinin
reveal
year
old
group
level
protect
exhibit
similar
valu
b
without
domin
particular
hemagglutinin
type
age
group
protect
rate
hemagglutinin
much
higher
hemagglutinin
type
b
howev
year
old
group
significantli
higher
protect
rate
observ
type
b
hemagglutinin
compar
two
type
last
three
epidem
season
valu
protect
rate
differ
particular
age
group
tabl
comparison
protect
rate
hemagglutinin
strain
especi
interest
type
influenza
viru
circul
popul
sinc
age
group
year
signific
increas
protect
rate
compar
previou
two
season
youngest
age
group
valu
higher
comparison
last
season
lower
season
howev
group
year
old
protect
rate
remain
similar
level
analyz
season
case
despit
appar
increas
protect
rate
age
group
valu
achiev
result
truli
alarm
show
valu
protect
rate
influenza
polish
popul
low
complic
influenza
may
hazard
health
lifethreaten
person
vaccin
especi
young
elderli
seriou
medic
condit
influenza
vaccin
effect
way
prevent
infect
fact
ignor
mani
peopl
conclud
basi
serolog
screen
sera
peopl
differ
age
group
epidem
season
result
confirm
circul
three
antigen
differ
influenza
strain
two
subtyp
influenza
viru
acalifornia
type
b
bmassachusett
protect
rate
exceed
age
group
demonstr
proport
peopl
vaccin
influenza
poland
low
situat
chang
peopl
vaccin
influenza
author
declar
conflict
interest
relat
articl
